Dr. Oshinski is well known for his collaborative efforts between Emory and Georgia Tech's Department of Biomedical Engineering, along with his dedication to advancing the technologies of MR imaging. One area of concentration is the development of Cardiovascular MRI for clinical and basic science applications. Dr. Oshinski has worked on development of the contrast-enhanced MRA and phase-contrast MR for rapid assessment of the aorta and the peripheral runoff vessels. He also Implemented SSFP cine imaging for rapid breath-hold assessment of cardiac function, IR recovery sequences for myocardial perfusion imaging, and creating a protocol for using MR coronary angiography to diagnose the proximal course of the coronary arteries.
Cleft and craniofacial disorders are my primary clinical and basic research interests. Even though the surgical repair of cleft lip and palate is highly effective, patients will continue to be faced with ongoing medical, dental, and surgical care. Surgical outcomes can be variable, and the patient's facial growth and development is primarily the result of their genetic composition. Therefore, much of my research focuses on the problems that can develop during the years that follow surgery.
Underdevelopment of the upper jaw is one of the main sequelae of cleft palate repair and causes maxillary hypoplasia. To uncover why this happens, I have assembled a team of collaborators that includes Drs. Nick Willett (Emory Department of Orthopedics), Gregory Gibson (Center for Integrative Genomics, Georgia Institute of Technology), and Michael Davis (Coulter Department of Biomedical Engineering at Georgia Tech and Emory University), all of whom are experts in the fields of bone and vascular biology. Our goal is to determine how cell autonomous and non-cell autonomous Jagged1 signaling during maxillary development contributes to final maxillary formation.
With assistance from Drs. Scott Boden (Emory Department of Orthopedics), Roberto Pacifici (Emory Department of Medicine), and Bob Taylor (Emory Department of Medicine), I am examining how intramembranous ossification of the maxillary and palatine bones contributes to later maxillary morphology. Dr. Greg Gibson (Director of the Center for Integrative Genomics, Georgia Tech) will help plan, execute, and analyze the RNA-seq data to identify the targets of Jagged1 signaling. We have already published our observations involving the bony phenotype and our conclusion that Wnt1-Cre;Jagged1 F/F mice are a viable model of post-natal maxillary hypoplasia. Once we have a wider understanding of maxillary development, we plan on developing targeted therapies for future in vitro and in vivo correction of maxillary hypoplasia in the Jag1CKO mice
Neuroimaging, neurostimulation, rehabilitation, neural plasticity, motor learning, stroke
My research interests are centered on understanding the adaptive capacity of the human nervous system in order to create innovative rehabilitation interventions to ameliorate disability and improve quality of life for individuals with neurologic impairment. My research laboratory is focused on translational neurorehabilitation in a highly collaborative atmosphere. Transdisciplinary collaborations are embraced at every opportunity in an effort to inform our work and contribute to the activities of other scientists. I also see these collaborations as a fertile training ground for students in the lab that come from neuroscience, medicine, biomedical engineering, physical therapy, computer science, etc.
Dr. Arbiser's research focuses on the regulation of angiogenesis and tumorigenesis by signal transduction pathways. Our laboratory has chosen three model systems to study these relationships. The first area is the common vascular birthmarks of children and their malignant counterparts, angiosarcomas. The second application of these studies are benign neoplasms which develop in the autosomal dominant syndrome tuberous sclerosis (TS). The third application of these studies is in the pathogenesis of malignant melanoma. Dr Arbiser has developed the hypothesis that oncogenes disrupt the balance between angiogenesis stimulators and inhibitors.
I have 2 areas of ongoing investigation. One focus is a C-type lectin-family receptor (CD303) expressed uniquely on the surface of human plasmacytoid dendritic cells. Data suggest that this receptor impacts function of these cells in innate and adaptive immunity. We have developed unique biochemical tools to better understand the structure and function of CD303 including identification of natural binding targets whether of self or non-self origin. Specific efforts focus on identifying the specific counter-receptors on these targets and better characterizing the impact of receptor-ligand engagement. A second focus involves deciphering the role of the Bcl-6 interacting transcriptional co-repressor MTA3 and BCL6 in B cell lymphomas, work done in collaboration with Dr. P. Wade at NIEHS, and translating this knowledge into diagnostically useful tools.
Dr. Waller's research focus is in enhancing immune reconstitution after stem cell transplant and developing cell therapy for anti-tumor immunology and in regenerative medicine. His current research activities include pre-clinical and clinical studies focused on the role of donor immune cells in optimizing anti-tumor immunity after allogenic transplantation, and the clinical application of autologous CD34+ cells in improving vascular function and facilitating neo-angiogenesis in patients with peripheral and coronary vascular disease. His NIH-funded basic research lab uses mouse models and performs immunological analyses of clinical samples from patients. He has active translational research activities and serves as a principal investigator on institutional and national cooperative group clinical trials.
Mara Schenker, MD is a clinician-scientist at Emory University. Her clinical practice is in orthopaedic trauma at Grady Memorial Hospital, and her interests include complex periarticular trauma, infection, nonunion, and malunion. Dr. Schenker performs approximately 600 complex trauma surgeries per year. Her research interests include host factors associated with delayed fracture healing (nutrition, infection, frailty, and others). Additional research interests include optimization of resident education.
The research interests of our laboratory are to understand the diverse and critical roles played by mRNA binding proteins and associated factors in the posttranscriptional regulation of gene expression in the nervous system, and investigate how these processes go awry in neurodevelopmental and neurodegenerative disorders. We investigate the normal mechanism, function and regulation of mRNA binding proteins in mRNA transport and local protein synthesis needed for neuronal development and synaptic plasticity. We investigate pathomechanisms for Fragile X syndrome (FXS) and other autism spectrum disorders, as well as two motor neuron diseases: spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are using mouse models of neurological diseases to assess the function of mRNA regulation and local protein synthesis in axon guidance, synapse development and neuronal signaling. Efforts are also underway to evaluate different therapeutic modalities in these mouse models of neurological diseases. Our research utilizes an integrated multi-disciplinary approach that involves cellular, molecular, biochemical, physiological, and behavioral methods and paradigms. These studies are expected to reveal new mechanisms important for neuronal development and function, and targeted approaches for therapeutic intervention that treat underlying molecular defects in SMA, Fragile X syndrome and autism spectrum disorders.